Tag: MONOGRAPH

  • Schisandra chinensis

    Chinese magnolia vine berry adaptogen

    A Chinese berry traditionally used as the ‘five flavors fruit’ for endurance, mental clarity, and hepatoprotection, characterized by schizandrins.

    Abstract

    Schisandra chinensis (Wu Wei Zi, “five flavors fruit”) is a climbing vine from China and Russia whose berries have been used for endurance, mental clarity, hepatoprotection, and longevity. The active constituents are lignans called schizandrins (schizandrin, gomisin A, gomisin N, and others). Modest hepatoprotective effects in liver injury models, antioxidant effects, and stress-tolerance effects have been documented. The schizandrins are CYP3A inducers, which has clinical drug interaction implications.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • PEG-MGF (Mechano Growth Factor)

    Pegylated IGF-1 splice variant

    A pegylated form of mechano growth factor (the IGF-1Ec splice variant) sold as a research peptide for muscle repair applications.

    Abstract

    PEG-MGF is a pegylated form of mechano growth factor (MGF), a splice variant of IGF-1 (IGF-1Ec) generated by exercise-induced muscle damage. MGF differs from systemic IGF-1 in containing a unique 24-residue C-terminal extension produced by alternative splicing of exon 5. The MGF C-terminal peptide alone (without the IGF-1 mature peptide) has been studied for muscle stem cell activation. Pegylation extends plasma half-life of the otherwise rapidly cleared peptide. The compound is sold as a research peptide; clinical evidence base in humans is sparse.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Valerian (Valeriana officinalis)

    Botanical sedative / GABAergic herb

    A perennial herb root traditionally used as a mild sedative, characterized by valerenic acid GABA-A modulation.

    Abstract

    Valeriana officinalis is a perennial herb whose root has been used for centuries as a mild sedative and anxiolytic. Active constituents include valerenic acid and related sesquiterpene acids, plus a complex mixture of valepotriates. Pharmacology includes GABA-A receptor modulation (valerenic acid binds the same receptor pocket as benzodiazepines but with different functional selectivity), modest adenosine A1 receptor agonism, and inhibition of GABA reuptake. Clinical evidence in primary insomnia is mixed; meta-analyses show modest improvements in sleep quality measures with effect sizes in the 0.2 to 0.4 range.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Ginkgo Biloba

    Maidenhair tree leaf extract

    Standardized extract of Ginkgo biloba leaves used for cognitive function and peripheral circulation, characterized by flavonoid glycosides and terpene lactones.

    Abstract

    Ginkgo biloba is the world’s oldest living tree species, with leaves used in traditional Chinese medicine and standardized extracts (EGb 761) marketed in Europe for cognitive impairment and peripheral arterial disease. Active constituents are flavonoid glycosides (24 percent in EGb 761) and terpene lactones (ginkgolides A, B, C; bilobalide; 6 percent). Pharmacology includes platelet activating factor (PAF) antagonism (ginkgolides), MAO inhibition (modest), and antioxidant activity. The clinical evidence base in dementia is mixed (large GEM and GuidAge trials negative); peripheral arterial disease evidence is more positive.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Exenatide

    GLP-1 receptor agonist (exendin-4)

    A synthetic version of the Gila monster venom peptide exendin-4, FDA-approved as Byetta (twice daily) and Bydureon (weekly) for T2DM.

    Abstract

    Exenatide (Byetta, Bydureon; CAS 141758-74-9; molecular weight 4186.57) is a synthetic version of exendin-4, a 39-amino-acid peptide originally isolated from Gila monster (Heloderma suspectum) venom. The compound is a GLP-1 receptor agonist with substantial structural difference from human GLP-1, providing resistance to DPP-4 cleavage. Exenatide was the first GLP-1 receptor agonist approved (Byetta, 2005); the extended-release formulation (Bydureon, 2012) provides once-weekly administration.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Mirtazapine

    Tetracyclic atypical antidepressant (NaSSA)

    A noradrenergic and specific serotonergic antidepressant; a tetracyclic with strong H1 antihistamine activity producing pronounced sedation and appetite stimulation.

    Abstract

    Mirtazapine ((R/S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine; CAS 85650-52-8; molecular formula C17H19N3; molecular weight 265.36) is a tetracyclic NaSSA (noradrenergic and specific serotonergic antidepressant) developed at Organon and approved by the FDA in 1996 under the trade name Remeron. Mechanism distinguishes the compound from the SSRI/SNRI class: rather than inhibiting transporters, mirtazapine antagonizes presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, increasing both norepinephrine and serotonin release. Concurrent 5-HT2A and 5-HT2C antagonism redirects the released serotonin preferentially to 5-HT1A receptors. Strong H1 histamine antagonism (Ki approximately 0.14 nM, comparable to first-generation antihistamines) produces sedation and weight gain, often dose-limiting at higher doses. The compound has minimal activity at muscarinic, dopaminergic, or transporter sites. Plasma half-life is 20 to 40 hours; metabolism is via CYP2D6, CYP3A4, and CYP1A2. Approved for major depressive disorder; widely used off-label for insomnia and as an appetite stimulant. Used as a reference compound in alpha-2 adrenergic and 5-HT2 receptor pharmacology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Moclobemide

    Reversible MAO-A inhibitor (RIMA)

    A morpholine benzamide reversible inhibitor of MAO-A (RIMA); the first MAOI that does not require dietary tyramine restriction.

    Abstract

    Moclobemide (4-chloro-N-(2-morpholin-4-ylethyl)benzamide; CAS 71320-77-9; molecular formula C13H17ClN2O2; molecular weight 268.74) is a morpholine benzamide reversible inhibitor of MAO-A (RIMA) developed at Roche and approved in Europe (1989) and Canada (1992) under the trade name Aurorix; never FDA approved for the US market. MAO-A selectivity ratio is approximately 100:1 over MAO-B at low doses. Plasma half-life is 1 to 4 hours; the short half-life dictates twice-daily dosing. Hepatic metabolism via CYP2C19 is the primary clearance pathway. Approved for major depressive disorder and social anxiety disorder. The eliminated tyramine restriction has not produced the expected clinical takeoff: efficacy is modestly inferior to TCAs in head-to-head trials, and the drug remains a niche option. Used as the canonical RIMA in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Topiramate

    Sulfamate-substituted monosaccharide / multifactorial anticonvulsant

    A sulfamate-substituted monosaccharide anticonvulsant with broad mechanism (sodium channels, GABA-A potentiation, AMPA antagonism, carbonic anhydrase inhibition); used for migraine prophylaxis and weight loss.

    Abstract

    Topiramate (2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; CAS 97240-79-4; molecular formula C12H21NO8S; molecular weight 339.36) is a sulfamate-substituted monosaccharide anticonvulsant developed at Johnson and Johnson and approved by the FDA in 1996 under the trade name Topamax. Mechanism is multifactorial: state-dependent sodium channel inhibition; GABA-A receptor potentiation at a non-benzodiazepine site; AMPA/kainate glutamate receptor antagonism; carbonic anhydrase inhibition (isozymes II and IV); high-voltage calcium channel inhibition. The carbonic anhydrase activity contributes to the characteristic adverse events: paresthesias (40 percent of patients), nephrolithiasis (1.5 percent), metabolic acidosis. Cognitive side effects are pronounced: word-finding difficulty, slowed mentation. Plasma half-life is 21 hours; metabolism is approximately 70 percent renal excretion unchanged. Approved for partial-onset and generalized tonic-clonic seizures, Lennox-Gastaut syndrome, migraine prophylaxis, and (with phentermine, as Qsymia) chronic weight management. Used as the canonical multifactorial anticonvulsant and as a reference carbonic anhydrase inhibitor in CNS pharmacology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Clomiphene

    Triphenylethylene SERM (mixed isomers)

    A racemic mixture of enclomiphene (anti-estrogen) and zuclomiphene (estrogen agonist); the prototype ovulation-inducing agent.

    Abstract

    Clomiphene (2-[4-[(E/Z)-2-chloro-1,2-diphenylvinyl]phenoxy]-N,N-diethylethanamine; CAS 911-45-5; molecular formula C26H28ClNO; molecular weight 405.96) is a triphenylethylene SERM developed at Merrell and approved by the FDA in 1967 under the trade name Clomid. The compound is sold as a racemic mixture of approximately 38 percent zuclomiphene ((Z)-isomer, an ER agonist) and 62 percent enclomiphene ((E)-isomer, an ER antagonist). The therapeutic effect in ovulation induction is driven primarily by enclomiphene-mediated antagonism of hypothalamic ER, releasing the negative feedback on GnRH and consequently increasing pituitary FSH and LH; the resulting follicular development drives ovulation. The zuclomiphene component is approximately 5-fold longer half-life than enclomiphene (zuclomiphene t1/2 approximately 30 days, enclomiphene t1/2 approximately 30 hours), causing the agonist component to dominate at later cycles and produce some unwanted estrogen-like effects (cervical mucus changes, antiestrogen rebound). Approved for ovulation induction in anovulatory women. Off-label use in male hypogonadism (induces endogenous testosterone via the same FSH/LH route) is common. Used as the canonical triphenylethylene SERM with HPG-stimulating activity.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Insulin (Research)

    Peptide hormone (51-amino-acid disulfide-linked dipeptide)

    The pancreatic peptide hormone insulin; the foundational glucose-regulatory hormone and a research probe for metabolic and anabolic biology.

    Abstract

    Insulin (CAS 9004-10-8; A-chain 21 amino acids, B-chain 30 amino acids; total molecular weight approximately 5808 Da for human insulin) is the pancreatic peptide hormone discovered by Banting and Best in 1921 (Nobel Prize 1923) and synthesized as recombinant human insulin (Humulin) in 1982 by Genentech, the first FDA-approved recombinant pharmaceutical. Pharmacologically, insulin binds the insulin receptor (IR) and the IGF-1 receptor (IGF-1R) with substantially higher affinity for IR. Receptor binding triggers tyrosine kinase activation of IRS-1/2 and downstream PI3K-Akt signaling, regulating glucose uptake (GLUT4 translocation), glycogen synthesis, lipogenesis, and protein synthesis. Modern formulations include rapid-acting analogs (lispro, aspart, glulisine), regular insulin, intermediate (NPH), long-acting (glargine, detemir, degludec), and ultra-long-acting (degludec). Approved indications: type 1 diabetes (essential), type 2 diabetes (when oral agents fail). The principal safety risk is hypoglycemia, severe enough to cause neuronal injury or death; insulin is among the leading drug-related causes of medical emergency department visits. Recreational anabolic use has been documented but is associated with high acute mortality. Used as the canonical metabolic hormone in academic biology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.